Childhood autism : aspects of growth factors and monoaminergic transporters in etiopathogenesis
Year: 2012
Type: dissertation
Study design: Clinical Trial
Abstract: Autism is a neuropsychiatric developmental disorder in which there is a dysfunction in social interaction and communication, and a combination of repetitive and stereotypic behavior.Disturbances in growth factors and monoaminergic neurotransmitter system have been postulated in autism.Selective serotonin reuptake inhibitors (SSRIs) have shown favorable effects in autism, and effects on growth factors elsewhere, but the relationships between these elements have not been investigated.Prior to treatment, head circumference (HC) was registered and insulin-like growth factor-1 (IGF-1) was measured in cerebrospinal fluid (CSF) in 25 children with autism, aged 2 to 16 years.Serum brain derived neurotrophic factor (BDNF) was analyzed and serotonin transporter (SERT) and dopamine transporter (DAT) binding were determined by single photon emission computed tomography (SPECT) in 15 autistic children, aged 5 to 16 years.Control groups were composed of 16 and 10 age-matched children without autism, aged 1 to 15 years and 7 to 14 years, respectively.Six-months' treatment with fluoxetine, an SSRI drug, was provided to 13 autistic children and symptoms were followed up using Autism Treatment Evaluation Checklist.The prior to treatment procedures were repeated 2 months after termination of treatment.Before treatment, CSF-IGF-1 concentration was lower in children with autism under 5 years of age (p=0.014)than in controls.A positive correlation was detected between CSF-IGF-1 and HC in autistic children (p=0.014).BDNF displayed a bimodal distribution in autistic individuals; concentrations were very low or high as compared with controls.At baseline, SERT binding capacity in SPECT was lower in autistic children in medial frontal cortex (p=0.002).Striatal DAT binding capacity was highest in the youngest autistic children, and then decreased with age, but in controls binding capacity increased with age.Fluoxetine elicited positive effects in communicative skills, sociability, and sensory awareness, particularly in six autistic children.These good responders exhibited a decrease in BDNF (p=0.03) as well as in striatal DAT binding (p=0.03).CSF-IGF-1 increased (p=0.003) but no correlation was detected with rates of clinical response.Fluoxetine was well tolerated.In conclusion, fluoxetine seems to modulate IGF-1, BDNF and the monoaminergic system, which are altered in autism.Fluoxetine could represent a useful adjunct therapy to conventional communication and behavioral therapies for children with autism.
Author: Ismo Makkonen
Institution: University of Eastern Finland
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: childhood autism, growth factors, insulin-like growth factor I, cerebrospinal fluid, brain-derived neurotrophic factor, serotonin transporter, dopamine transporter, fluoxetine, selective serotonin reuptake inhibitors, head circumference, treatment response, children with autism, striatum, frontal cortex, social communication, sociability, sensory awareness
Open Access status: green
OpenAlex ID: W3096447475
